References
You can view the abstracts for the references listed below via the National Library of Medicine's PubMed service. Just click the PubMed links. Click here to view the PubMed disclaimer and copyright notice.
- 1.
Bree RT, Stenson-Cox C, Grealy M, Byrnes L, Gorman AM, Samali A. Cellular longevity: role of apoptosis and replicative senescence. Biogerontology. 2002;3:195-206.
Link to abstract on PubMed - 2.
Fulda S, Debatin KM. Apoptosis signaling in tumor therapy. Ann N Y Acad Sci. 2004;1028:150-156.
Link to abstract on PubMed - 3.
Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med. 2005;258:479-517.
Link to abstract on PubMed - 4.
Ziegler U, Groscurth P. Morphological features of cell death. News Physiol Sci. 2004;19:124-128.
Link to abstract on PubMed - 5.
Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420-430.
Link to abstract on PubMed - 6.
Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov. 2008;7:1001-1012.
Link to abstract on PubMed - 7.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
Link to abstract on PubMed - 8.
Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798-4811.
Link to abstract on PubMed - 9.
Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer. CA Cancer J Clin. 2005;55:178-194.
Link to abstract on PubMed - 10.
Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol. 2005;23:9394-9407.
Link to abstract on PubMed - 11.
Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312-1316.
Link to abstract on PubMed - 12.
Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest. 2005;115:2665-2672.
Link to abstract on PubMed - 13.
Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005;5:876-885.
Link to abstract on PubMed - 14.
Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev. 2005;57:187-215.
Link to abstract on PubMed - 15.
Reed JC. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol. 2006;3:388-398.
Link to abstract on PubMed - 16.
Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood. 2005;106:408-418.
Link to abstract on PubMed - 17.
Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004;432:307-315.
Link to abstract on PubMed - 18.
Boogerd W, de Gast GC, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer. 2007;109:306-312.
Link to abstract on PubMed - 19.
Gu Y, Swisher SG, Ajani JA, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006;106:1017-1025.
Link to abstract on PubMed - 20.
Kakolyris S, Kalbakis K, Potamianou A, et al. Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study. Oncology. 2006;70:273-279.
Link to abstract on PubMed - 21.
Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412-425.
Link to abstract on PubMed - 22.
Lindholm P, Valavaara R, Aitasalo K, et al. Preoperative hyperfractionated accelerated radiotherapy and radical surgery in advanced head and neck cancer: a prospective phase II study. Radiother Oncol. 2006;78:146-151.
Link to abstract on PubMed - 23.
Masi G, Marcucci L, Loupakis F, et al. First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Ann Oncol. 2006;17:1249-1254.
Link to abstract on PubMed - 24.
Massacesi C, La Cesa A, Marcucci F, et al. Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. Oncology. 2006;70:294-300.
Link to abstract on PubMed - 25.
Mukai M, Oida Y, Tajima T, et al. Alternating hepatic arterial infusion and systemic chemotherapy for stage IV colorectal cancer with synchronous liver metastasis. Oncol Rep. 2006;16:865-870.
Link to abstract on PubMed - 26.
Pittman KB, Olver IN, Koczwara B, et al. Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. Br J Cancer. 2006;95:1309-1313.
Link to abstract on PubMed - 27.
Raez LE, Santos ES, Lopes G, et al. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer. 2006;53:347-353.
Link to abstract on PubMed - 28.
Scartozzi M, Falcone A, Pucci F, et al. Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. Tumori. 2006;92:384-388.
Link to abstract on PubMed